N/A
N=36
Antihypertensive Effect of Fermented Milk With Lactococcus Lactis on Prehypertensive Subjects
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT02670811 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcome: Primary: Systolic Blood Pressure Measurements — 131.8; 134.3; 122.1; 127.4 mmHg — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Fermented milk (Dietary_supplement); Acidified milk (Dietary_supplement)
- Age
- Adult · 25+ yrs
- Sex
- All
- Sponsor
- Centro de Investigación en Alimentación y Desarrollo A.C.
- Primary completion
- Dec 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Systolic Blood Pressure Measurements |
131.8; 134.3; 122.1; 127.4; 121.3; 125.8 | <0.05 sig |
| SECONDARY Diastolic Blood Pressure Measurements |
87.7; 89.4; 82.3; 85.9; 80.8; 84.2 | <0.05 sig |
| SECONDARY Total Cholesterol Measurements |
190.1; 178.1; 180.7; 189.8 | <0.05 sig |
| SECONDARY Low Density Lipoproteins Measurements |
127.1; 114.7; 116.6; 122.7 | <0.05 sig |
| SECONDARY High Density Lipoproteins |
37.9; 37.8; 43.2; 42.4 | <0.05 sig |
| SECONDARY Triglycerides Measurements |
137.5; 144.3; 103.6; 124.9 | <0.05 sig |
Summary
The objective of the present work was to evaluate the antihypertensive effect associated with the consumption of fermented milk with Lactococcus lactis NRRL-B50571 on prehypertensive subjects.
Eligibility Criteria
Inclusion Criteria
- Systolic blood pressure >130 mmHg
- Diastolic blood pressure > 85 mmHg
Exclusion Criteria
- Pregnant women
- Cardiovascular diseases
- Diabetes
- Cancer
- Dairy allergy
- Lactose intolerance
- Patients receiving angiotensin converting enzyme inhibitors as pharmacological therapy
Data sourced from ClinicalTrials.gov (NCT02670811). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.